Evidence map›Paper›PMID 41783831›Full record

ArticleBrain communications2026

Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.

Nirosen Vijiaratnam, Christine Girges, Arthur Mitchell, Dilan Athauda, Riona Fumi, Jennifer Hay, Nicola O'Reilly, Huw Morris, Camille Carroll, Michele T M Hu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Seeing Invisible Oligomers: Rethinking α-Synuclein Pathology Through Proximity Ligation Assay.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nirosen VijiaratnamDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Christine GirgesDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Arthur MitchellNeurodegenration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Dilan AthaudaNeurodegenration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Riona FumiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Jennifer HayNeurodegenration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Nicola O'ReillyNeurodegenration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Huw MorrisDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.ORCID https://orcid.org/0000-0002-5473-3774
Camille CarrollTranslational and Clinical Research Institute Clinical Ageing Research Unit, Newcastle University, Newcastle, UK.
Michele T M HuNuffield Department of CLinical Neurosciences, Oxford University and Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.ORCID https://orcid.org/0000-0001-6382-5841
Monty A SilverdaleManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9NQ, UK.
Gordon DuncanUniversity of Edinburgh and Western General Hospital, Edinburgh EH4 2XU, UK.
Amanda HeslegraveUK Dementia Research Institute, University College London, London NW1 3BT, UK.
Eliza ChaiAlamar Biosciences, Inc, Fremont, CA 94538, USA.
Sonia GandhiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
Thomas FoltynieDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.ORCID https://orcid.org/0000-0003-0752-1813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are currently no validated peripheral biomarkers for the diagnosis, differentiation or progression of the neurodegenerative synucleinopathies, Parkinson's disease and multiple system atrophy. Diagnostic biomarkers that reflect the disease mechanisms or progression biomarkers that change with disease severity would be extremely valuable for assessing disease-modifying therapies. Our objective was to explore putative protein biomarkers of Parkinson's disease and multiple system atrophy, in relation to clinical disease severity, using the nucleic acid-linked immuno-sandwich assay central nervous system disease panel for biomarker quantification. We used the nucleic acid-linked immuno-sandwich assay CNS disease panel to test plasma from 161 Parkinson's disease patients collected at three time points (0, 48, 96 weeks) and serum from 43 multiple system atrophy patients at three time points (0, 24, 48 weeks) and compared results to paired plasma and serum samples collected from (

Indexed as

biomarkermultiple system atrophyParkinson’s diseaseproteomics

Identifiers

PMID41783831
PMCPMC12954390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.